

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/773,986
Filing Date	February 5, 2004
First Named Inventor	Jenny Louie-HELM
Art Unit	1615
Examiner Name	Blessing M. FUBARA
Attorney Docket Number	3100-0003.10

Mail Stop **Amendment****ENCLOSURES (Check all that apply)**

- |   |  |  |
|---|--|--|
| <input type="checkbox"/> No fee due<br><input checked="" type="checkbox"/> Fee Transmittal<br><input checked="" type="checkbox"/> Fee(s) due<br><input checked="" type="checkbox"/> Fee Transmittal<br><input checked="" type="checkbox"/> Check for <b>\$120.00</b><br><input checked="" type="checkbox"/> Charge any underpayment or credit any overpayment to Deposit Account No. 18-0580<br><input checked="" type="checkbox"/> Return postcard<br><input checked="" type="checkbox"/> Response<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input checked="" type="checkbox"/> Extension of Time Request (1 mo)<br><input type="checkbox"/> Express Abandonment Request<br><input type="checkbox"/> Information Disclosure Statement & Form(s) PTO-1449<br><input type="checkbox"/> Copy(ies) of cited reference(s)<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts / Incomplete Application<br><input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s): | <input type="checkbox"/> After Allowance Communication to a Technology Center (TC)<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input type="checkbox"/> Other Enclosure(s) (please identify below): |
|---|--|--|

Remarks:


**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual Name (print/type)	<b>Karen Cnaan, Reg. No. 42,382</b> <b>Reed Intellectual Property Law Group</b>	Telephone	<b>(650) 251-7700</b>
Signature	<i>Karen Cnaan</i>	Date	<b>June 9, 2005</b>

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Name (print/type)	<b>Yesenia Cuevas</b>	Date	<b>June 9, 2005</b>
Signature	<i>Yesenia Cuevas</i>		



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of:

Jenny Louie-HELM et al.

Confirmation No.: 7141

Serial No.: 10/773,986

Group Art Unit: 1615

Filing Date: February 5, 2004

Examiner: Blessing M. FUBARA

Title: FORMULATION OF AN ERODIBLE, GASTRIC RETENTIVE ORAL DOSAGE FORM  
USING IN VITRO DISINTEGRATION TEST DATA

**RESPONSE UNDER 37 C.F.R. § 1.111**

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Responsive to the non-final Office Action for this matter, which bears a mailing date of March 8, 2005, please reconsider this application in light of the amendments and remarks set forth in this paper. The fee for a one-month extension accompanies this filing.

**LISTING OF THE CLAIMS**

The listing of the claims is set forth on pages 2 to 4 of this paper.

**REMARKS:**

Applicants' arguments in support of this application are presented in the remarks set forth on pages 5 to 11 of this paper.

**ATTACHMENT:**

Attached to the end of this paper is a copy of Chapter 15 from J.G. Wagner, BIOPHARMACEUTICS AND RELEVANT PHARMACOKINETICS, Ch. 15, Drug Intelligence Publications, Hamilton, IL (1971).

06/14/2005 WASFAW1 00000039 10773986

01 FC:1251

120.00 0P